Cancer:转移性非小细胞肺癌化疗治疗模式

2015-04-29 徐媛媛译 MedSci原创

在临床试验中,治疗转移性非小细胞肺癌(NSCLC)的新方法可改善患者生存状况。然而,只有少数患者接受系统性治疗。本文对来自加拿大安大略省的转移性非小细胞肺癌患者的治疗策略和结果进行了分析报道。 通过多个相关数据库数据的筛查,我们确定了2005~2009年间诊断为Ⅳ期非小细胞肺癌患者。本研究收纳了转移性非小细胞肺癌(NSCLC)患者8113例,中位年龄为68岁,39%患有腺癌,14%的患者有鳞状细

在临床试验中,治疗转移性非小细胞肺癌(NSCLC)的新方法可改善患者生存状况。然而,只有少数患者接受系统性治疗。本文对来自加拿大安大略省的转移性非小细胞肺癌患者的治疗策略和结果进行了分析报道。

通过多个相关数据库数据的筛查,我们确定了2005~2009年间诊断为Ⅳ期非小细胞肺癌患者。本研究收纳了转移性非小细胞肺癌(NSCLC)患者8113例,中位年龄为68岁,39%患有腺癌,14%的患者有鳞状细胞癌,43%的患者有非小细胞肺癌,该比例高于预期值。只有24%的患者接受了一线化疗,其中31%接受了二线化疗。更多的患者接受系统性(从2005年的19%到2009年的26%,P <0.0001)。不到70岁的患者或患有腺癌的患者更有可能接受系统性治疗(P <0.0001)。忽略患者年龄,与接收11.6个月的无培美曲塞的双铂类药物治疗相比,选择接受一线顺铂-吉西他滨治疗的中位生存期更长(P =0.0002).非鳞癌的患者接受二线培美曲塞治疗中位存活期比接受多西他赛时间长(19.8 vs 14.1个月,P <0.0001)。

大多数转移性非小细胞肺癌患者仍未得到系统性治疗。那些包括老年患者的被选入一线和二线系统治疗的生存结果与临床试验的结果具有可比性。老年患者和鳞癌患者不太可能接受化疗。这项研究中显示出的低水平的治疗利用率值得进一步调查

原始出处

Sacher AG1, Le LW, Lau A, Earle CC, Leighl NB.Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated? Cancer. 2015 Apr 17

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=24437, encodeId=cda62443e8d, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 14:18:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059500, encodeId=812c2059500c4, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Feb 21 05:42:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386153, encodeId=d7321386153ea, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471991, encodeId=864814e19917b, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555140, encodeId=c7231555140d6, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22299, encodeId=3c1e2229901, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Thu Apr 30 09:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22263, encodeId=2aee2226334, content=真实世界结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 29 21:07:00 CST 2015, time=2015-04-29, status=1, ipAttribution=)]
    2015-05-21 cement123

    good

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=24437, encodeId=cda62443e8d, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 14:18:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059500, encodeId=812c2059500c4, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Feb 21 05:42:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386153, encodeId=d7321386153ea, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471991, encodeId=864814e19917b, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555140, encodeId=c7231555140d6, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22299, encodeId=3c1e2229901, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Thu Apr 30 09:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22263, encodeId=2aee2226334, content=真实世界结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 29 21:07:00 CST 2015, time=2015-04-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=24437, encodeId=cda62443e8d, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 14:18:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059500, encodeId=812c2059500c4, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Feb 21 05:42:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386153, encodeId=d7321386153ea, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471991, encodeId=864814e19917b, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555140, encodeId=c7231555140d6, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22299, encodeId=3c1e2229901, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Thu Apr 30 09:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22263, encodeId=2aee2226334, content=真实世界结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 29 21:07:00 CST 2015, time=2015-04-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=24437, encodeId=cda62443e8d, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 14:18:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059500, encodeId=812c2059500c4, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Feb 21 05:42:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386153, encodeId=d7321386153ea, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471991, encodeId=864814e19917b, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555140, encodeId=c7231555140d6, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22299, encodeId=3c1e2229901, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Thu Apr 30 09:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22263, encodeId=2aee2226334, content=真实世界结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 29 21:07:00 CST 2015, time=2015-04-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=24437, encodeId=cda62443e8d, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 14:18:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059500, encodeId=812c2059500c4, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Feb 21 05:42:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386153, encodeId=d7321386153ea, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471991, encodeId=864814e19917b, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555140, encodeId=c7231555140d6, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22299, encodeId=3c1e2229901, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Thu Apr 30 09:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22263, encodeId=2aee2226334, content=真实世界结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 29 21:07:00 CST 2015, time=2015-04-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=24437, encodeId=cda62443e8d, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 14:18:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059500, encodeId=812c2059500c4, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Feb 21 05:42:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386153, encodeId=d7321386153ea, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471991, encodeId=864814e19917b, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555140, encodeId=c7231555140d6, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22299, encodeId=3c1e2229901, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Thu Apr 30 09:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22263, encodeId=2aee2226334, content=真实世界结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 29 21:07:00 CST 2015, time=2015-04-29, status=1, ipAttribution=)]
    2015-04-30 chenhui888

    继续学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=24437, encodeId=cda62443e8d, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 14:18:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059500, encodeId=812c2059500c4, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Feb 21 05:42:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386153, encodeId=d7321386153ea, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471991, encodeId=864814e19917b, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555140, encodeId=c7231555140d6, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Fri May 01 07:42:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22299, encodeId=3c1e2229901, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Thu Apr 30 09:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22263, encodeId=2aee2226334, content=真实世界结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Apr 29 21:07:00 CST 2015, time=2015-04-29, status=1, ipAttribution=)]
    2015-04-29 medcardio

    真实世界结果

    0

相关资讯

JTO:肿瘤低代谢预示早期非小细胞肺癌患者更高生存率

功能分子影像是从分子水平在活体研究细胞功能代谢的全新领域,是分子生物学、生物化学、数据图象处理等多学科融合的结果。正电子发射断层扫描(Positron emission tomography, PET)即是功能分子影像的代表,它可显示机体及病灶组织的细胞代谢、增值状况,是非常灵敏的诊断及评价肿瘤生物学特性的先进的分子影像技术。PET能在肿瘤大小改变之前即能检测到其功能代谢异常,能够为临床提供定位、

Ann Oncol:MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究

背景:KRAS突变在25%的非小细胞肺癌(NSCLC)患者上检测到,对这一亚群的靶向治疗药物还没有得到批准的。Trametinib,选择性变构的MEK1/MEK2抑制剂,在KRAS突变的非小细胞肺癌的临床前和临床研究上具有活性。我们报告了一项trametinib相比于多西他赛用于KRAS突变的晚期非小细胞肺癌患者的II期临床研究。 患者和方法:符合条件的患者为组织学证实为KRAS突变的非小细胞肺

Clin Cancer Res:色瑞替尼对ALK阳性的非小细胞肺癌有显著的抗肿瘤活性

目的:间变性淋巴瘤激酶(ALK)的重组在针对ALK抑制剂克唑替尼和色瑞替尼敏感性的非小细胞肺癌(NSCLC)上是重要的靶标。为确定克唑替尼和色瑞替尼先后次序的治疗效果,我们对采用两种药剂治疗ALK阳性患者的案例进行了回顾性分析。 实验设计:我们确定了四个机构中由克唑替尼和色瑞替尼治疗的73名ALK阳性的非小细胞肺癌患者。对克唑替尼和色瑞替尼治疗的医疗记录进行了审查,确定总生存期(OS)和无进展生

JTO:非小细胞肺癌患者在大型肿瘤中心放化疗效果更佳

据最新研究报道,III期非小细胞肺癌(NSCLC)患者在拥有丰富经验的治疗中心中进行化疗和放射治疗(CCRT)的总生存期更长,无论该中心是学术或社区癌症中心。肺癌是美国癌症相关死亡的主要原因,每年有224000人新诊断为肺癌,而死于肺癌的则每年有159000人,其中非小细胞肺癌占85%。肺癌的阶段是由肿瘤的大小、淋巴结的转移程度和位置以及肿瘤是否已经发生远处转移决定的。大约四分之一的非小细胞肺癌病

JTO:Alectinib能用于ALK阳性的耐药的非小细胞肺癌脑转移治疗

Crizotinib和 Ceritinib是两种重要的ALK抑制剂,主要用于ALK阳性的非小细胞肺癌(NSCLC),然而,也面临患者快速耐药问题。以往研究表明Ceritinib对Crizotinib耐药的ALK阳性的NSCLC患者。那么,患者也对Ceritinib耐药,该如何处理呢?下一代ALK抑制剂Alectinib可能能解决这个问题。本研究发表在JTO上,主要用于ALK重排阳性的NSCLC患者

Lung Cancer:EGFR酪氨酸激酶抑制剂用于EGFR阳性突变的非小细胞肺癌的安全性分析

目的:三个表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)- 阿法替尼,厄洛替尼,和吉非替尼用于EGFR阳性突变的非小细胞肺癌(NSCLC)患者的治疗。由于患者长期接触表皮生长因子受体酪氨酸激酶抑制剂,这些药物对这些人产生的毒理学性质可能不同于那些未长期接触的患者。我们对这三个表皮生长因子受体酪氨酸激酶抑制剂治疗EGFR阳性突变的NSCLC患者发生严重不良反应的频率(AES)进行比较。